Michael Pogorzelski

Essen, NW, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 21 publications

Pre-existing systemic immune state and dynamic myeloid remodeling shape response to neoadjuvant PD-L1 blockade.

Pre-existing systemic immune state and dynamic myeloid remodeling shape response to neoadjuvant PD-L1 blockade.

Journal: Journal for immunotherapy of cancer

Published: July 31, 2026

Tumor-associated neutrophils and macrophages differentially affect T cell biology in the head and neck cancer tumor microenvironment.

Tumor-associated neutrophils and macrophages differentially affect T cell biology in the head and neck cancer tumor microenvironment.

Journal: Journal of leukocyte biology

Published: July 13, 2026

LLM-Generated Lay-Language Protocols for Molecular Tumor Board Patients: Evaluation of Quality and Clinical Usability.

LLM-Generated Lay-Language Protocols for Molecular Tumor Board Patients: Evaluation of Quality and Clinical Usability.

Journal: Journal of medical Internet research

Published: April 22, 2026

Differential effects of prior versus concomitant Steroid and Antibiotic Treatment on Immunotherapy Efficacy - A Pooled Analysis of the RAMONA, INTEGA, OPTIM, ELDORANDO, FORCE, TITAN-RCC and TITAN-TCC Trials of the German AIO Study Group.

Differential effects of prior versus concomitant Steroid and Antibiotic Treatment on Immunotherapy Efficacy - A Pooled Analysis of the RAMONA, INTEGA, OPTIM, ELDORANDO, FORCE, TITAN-RCC and TITAN-TCC Trials of the German AIO Study Group.

Journal: British journal of cancer

Published: July 02, 2025

Safety and activity of tarlatamab in combination with a PD-L1 inhibitor as first-line maintenance therapy after chemo-immunotherapy in patients with extensive-stage small-cell lung cancer (DeLLphi-303): a multicentre, non-randomised, phase 1b study.

Safety and activity of tarlatamab in combination with a PD-L1 inhibitor as first-line maintenance therapy after chemo-immunotherapy in patients with extensive-stage small-cell lung cancer (DeLLphi-303): a multicentre, non-randomised, phase 1b study.

Journal: The Lancet. Oncology

Published: June 16, 2025

ABO-Blood Group Associates With Survival Outcomes in Patients With Metastatic Non-Small Cell Lung Cancer Treated With Pembrolizumab Monotherapy.

ABO-Blood Group Associates With Survival Outcomes in Patients With Metastatic Non-Small Cell Lung Cancer Treated With Pembrolizumab Monotherapy.

Journal: Thoracic cancer

Published: January 21, 2025

PD-L1 expression associates with favorable survival of patients with cancer of unknown primary (CUP) not treated with checkpoint inhibitors.

PD-L1 expression associates with favorable survival of patients with cancer of unknown primary (CUP) not treated with checkpoint inhibitors.

Journal: European journal of cancer (Oxford, England : 1990)

Published: June 26, 2024

Comprehensive biomarker diagnostics of unfavorable cancer of unknown primary to identify patients eligible for precision medical therapies.

Comprehensive biomarker diagnostics of unfavorable cancer of unknown primary to identify patients eligible for precision medical therapies.

Journal: European journal of cancer (Oxford, England : 1990)

Published: December 12, 2023

P-move: a randomized control trial of exercise in patients with advanced pancreatic or biliary tract cancer (aPBC) receiving beyond first-line chemotherapy.

P-move: a randomized control trial of exercise in patients with advanced pancreatic or biliary tract cancer (aPBC) receiving beyond first-line chemotherapy.

Journal: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer

Published: November 30, 2023

Investigation of screening questions to identify insomnia in cancer patients.

Investigation of screening questions to identify insomnia in cancer patients.

Journal: Scientific reports

Published: September 11, 2023

Impact of encorafenib on survival of patients with BRAFV600E-mutant metastatic colorectal cancer in a real-world setting.

Impact of encorafenib on survival of patients with BRAFV600E-mutant metastatic colorectal cancer in a real-world setting.

Journal: Journal of cancer research and clinical oncology

Published: July 05, 2023

Favorable survival outcomes in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer sequentially treated with a tyrosine kinase inhibitor and osimertinib in a real-world setting.

Favorable survival outcomes in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer sequentially treated with a tyrosine kinase inhibitor and osimertinib in a real-world setting.

Journal: Journal of cancer research and clinical oncology

Published: December 13, 2022

Showing 1-12 of 21

Last Updated: 09/26/2026